Treatment and outcome of breast implant-associated anaplastic large cell lymphoma: a population-based cohort study in the Netherlands

Author(s):
Meeuwes, F.O.; Brink, M.; Poel, M.W.M. van der; Serroukh, Y.I.M.; Vermaat, J.S.P.; Huls, G.A.; Boer, M. de; Jong, D. de; Plattel, W.J.; Nijland, M.
Published
2025
Publication type
Article / Letter to editor

Abstract

The optimal treatment of patients with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) that underwent incomplete resection, have advanced stage disease or relapse after resection remains unknown. We describe the treatment and outcome of all 91 Dutch BIA-ALCL patients up to 2023. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Ann Arbor stage I was frequently encountered (74%) compared to stage II (13%) and stage IV (11%). First-line treatment of stage I patients consisted mostly of surgery (88%). Stage II patients were treated with chemotherapy (CT) (67%) or underwent surgery (33%). All stage IV patients received CT. In total, 30% of patients (n = 27) received CT. Relapse frequently occurred (60%) in stage IV disease. The 2-year PFS and OS for stage I, II and IV were 89 and 98%, 83 and 92% and 50 and 90%, respectively. Following second-line treatment, all but one patient remained in remission.

Breast-implant associated anaplastic large cell lymphomaBIA-ALCLoutcometreatmentpopulation-based cohort study
Date issued
2025-07-08
Language
English
Publisher
TAYLOR & FRANCIS LTD
Is part of
Leukemia & Lymphoma (2025), Vol. 66, no. 11, p. 2064-2070
hdl
1887/4299584
doi
10.1080/10428194.2025.2530167